<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01954147</url>
  </required_header>
  <id_info>
    <org_study_id>SC/GLP-1</org_study_id>
    <nct_id>NCT01954147</nct_id>
  </id_info>
  <brief_title>Umbilical Cord Mesenchymal Stem Cells and Liraglutide in Diabetes Mellitus</brief_title>
  <official_title>Umbilical Cord Mesenchymal Stem Cell Infusion With Liraglutide in Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Diabetes Care Center of Nanjing Military Command</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Diabetes Care Center of Nanjing Military Command</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Umbilical cord mesenchymal stem cells (SC) transplantation was a novel therapy for diabetes&#xD;
      mellitus, with less side effects and more advantages. Clinical trials had verified that good&#xD;
      metabolic control would be achieved when Liraglutide (GLP-1) was added to the conventional&#xD;
      therapies. The investigators hypothesized that the combined therapy of umbilical cord&#xD;
      mesenchymal stem cells transplantation and Liraglutide in type 2 diabetes mellitus will aid&#xD;
      the differentiation of stem cells into insulin-producing cells, improve the survival of&#xD;
      differentiated cells, protect the residual beta-cells and improve insulin secreting function,&#xD;
      so as to achieve a favorable glucose homeostasis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">October 2015</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1C</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fasting Blood Glucose</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>SC-GLP-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Umbilical Cord Mesenchymal Stem Cell Infusion Combined With Liraglutide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Umbilical Cord Mesenchymal Stem Cell Infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GLP-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Liraglutide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard Medical Treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLP-1</intervention_name>
    <description>GLP-1 therapy</description>
    <arm_group_label>GLP-1</arm_group_label>
    <arm_group_label>SC-GLP-1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SC</intervention_name>
    <description>Stem cell infusion</description>
    <arm_group_label>SC</arm_group_label>
    <arm_group_label>SC-GLP-1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard Medical Treatment</intervention_name>
    <description>Standard Medical Treatment</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>GLP-1</arm_group_label>
    <arm_group_label>SC</arm_group_label>
    <arm_group_label>SC-GLP-1</arm_group_label>
    <other_name>SMT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female patients age 35 to 65 years of age.&#xD;
&#xD;
          -  Ability to provide written informed consent.&#xD;
&#xD;
          -  Mentally stable and able to comply with the procedures of the study protocol.&#xD;
&#xD;
          -  Clinical history compatible with type 2 diabetes (T2DM) as defined by ADA(1997) on the&#xD;
             Diagnosis and classification of Diabetes Mellitus&#xD;
&#xD;
          -  Basal C-peptide 0.5-2.0 ng/mL&#xD;
&#xD;
          -  HbA1c ≥ 7.5 and ≤ 11% before standard medical therapy (SMT).&#xD;
&#xD;
          -  Patients must have been treated with SMT for 1-4 months prior to matching. Insulin&#xD;
             dose and metformin doses should be stable over 1 month prior to matching.&#xD;
&#xD;
          -  HbA1c ≥ 7.5 and ≤ 10% at time of matching.&#xD;
&#xD;
          -  Total insulin daily dose (TDD) at time of matching should not exceed 1.0 units/day/kg&#xD;
&#xD;
          -  18.5 kg/㎡≤BMI≤40.0kg/㎡&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Abnormal liver function &gt;2.5 x ULN&#xD;
&#xD;
          -  Evidence of renal dysfunction:serum creatinine &gt; 1.5 mg/dl (males) and 1.3 mg/dl&#xD;
             (females).&#xD;
&#xD;
          -  Gastrointestinal operation history.&#xD;
&#xD;
          -  Type 1 Diabetes mellitus; DKA; secondary diabetes.&#xD;
&#xD;
          -  Uncontrolled blood Pressure: SBP &gt;180 mmHg or DBP &gt;100 mmHg at the time of matching.&#xD;
&#xD;
          -  Evidence of cardiovascular disease, existing congestive cardiac failure on physical&#xD;
             exam and/or acute coronary syndrome in past 6 months.&#xD;
&#xD;
          -  Presence of active proliferative diabetic retinopathy or macular edema.&#xD;
&#xD;
          -  Any acute or chronic infectious condition that in the criteria of the investigator&#xD;
             would be a risk for the patient.&#xD;
&#xD;
          -  For female participants: Positive pregnancy test, presently breast-feeding, or&#xD;
             unwillingness to use effective contraceptive measures for the duration of the study.&#xD;
             For male participants: intent to procreate 3 months before or after the intervention&#xD;
             or unwillingness to use effective measures of contraception. Oral contraceptives,&#xD;
             Norplant?, Depo-Provera?, and barrier devices with spermicide are acceptable&#xD;
             contraceptive methods; condoms used alone are not acceptable.&#xD;
&#xD;
          -  Active infection including hepatitis C, HIV, or TB as determined by a positive skin&#xD;
             test or clinical presentation, or under treatment for suspected TB.&#xD;
&#xD;
          -  Subjects that are being treated with any medication that could interfere with the&#xD;
             outcome of the study such as: Thiazolidinediones and other glucagon like peptide 1&#xD;
             (GLP-1) analogues (Exenatide, Byetta), Pramlintide (Amylin), Dipeptidyl-peptidase IV&#xD;
             (DPP-IV) inhibitors (i.e. Sitagliptin, Januvia)&#xD;
&#xD;
          -  Any known or suspected allergy to liraglutide or other relevant products.&#xD;
&#xD;
          -  Evidence of thyroid adverse events (serum calcitonin increase, goiter, thyroid cancer,&#xD;
             et al) or pancreatitis caused by other GLP-1 analogues.&#xD;
&#xD;
          -  Subjects with past history or family history of Medullary Thyroid Carcinoma(MTC) or&#xD;
             Multiple Endocrine Neoplasia Syndrome Type 2(MEN2) .&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiangjin Xu, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Diabetes Care Center of Nanjing Millitary Command</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Diabetes Care Center of Nanjing Military Command</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <study_first_submitted>August 13, 2013</study_first_submitted>
  <study_first_submitted_qc>September 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 1, 2013</study_first_posted>
  <last_update_submitted>February 19, 2014</last_update_submitted>
  <last_update_submitted_qc>February 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

